Literature DB >> 10449438

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

G R Hill1, T Teshima, A Gerbitz, L Pan, K R Cooke, Y S Brinson, J M Crawford, J L Ferrara.   

Abstract

We demonstrate an increase in graft-versus-host disease (GVHD) after experimental bone marrow transplant (BMT) when cyclophosphamide (Cy) is added to an otherwise well-tolerated dose (900 cGy) of total body irradiation (TBI). Donor T cell expansion on day +13 was increased after conditioning with Cy/TBI compared with Cy or TBI alone, although cytotoxic T lymphocyte (CTL) function was not altered. Histological analysis of the gastrointestinal tract demonstrated synergistic damage by Cy/TBI and allogeneic donor cells, which permitted increased translocation of LPS into the systemic circulation. TNF-alpha and IL-1 production in response to LPS was increased in BMT recipients after Cy/TBI conditioning. Neutralization of IL-1 significantly reduced serum LPS levels and GVHD mortality, but it did not affect donor CTL activity. By contrast, neutralization of TNF-alpha did not prevent GVHD mortality but did impair CTL activity after BMT. When P815 leukemia cells were added to the bone marrow inoculum, allogeneic BMT recipients given the TNF-alpha inhibitor relapsed at a significantly faster rate than those given the IL-1 inhibitor. To confirm that the role of TNF-alpha in graft versus leukemia (GVL) was due to effects on donor T cells, cohorts of animals were transplanted with T cells from either wild-type mice or p55 TNF-alpha receptor-deficient mice. Recipients of TNF-alpha p55 receptor-deficient T cells demonstrated a significant impairment in donor CTL activity after BMT and an increased rate of leukemic relapse compared with recipients of wild-type T cells. These data highlight the importance of conditioning in GVHD pathophysiology, and demonstrate that TNF-alpha is critical to GVL mediated by donor T cells, whereas IL-1 is not.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449438      PMCID: PMC408528          DOI: 10.1172/JCI6896

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immune responses in rats.

Authors:  J H Exon; G M Henningsen; L D Koller; P A Talcott
Journal:  Int J Immunopharmacol       Date:  1986

2.  Genetic nomenclature for loci controlling mouse lymphocyte antigens.

Authors:  H C Morse; F W Shen; U Hämmerling
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  Comparison of murine lymphokine-activated killer cells, natural killer cells, and cytotoxic T lymphocytes.

Authors:  V J Merluzzi
Journal:  Cell Immunol       Date:  1985-10-01       Impact factor: 4.868

4.  IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-gamma.

Authors:  K Kichian; F P Nestel; D Kim; P Ponka; W S Lapp
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

5.  Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis.

Authors:  D C Snover; S A Weisdorf; N K Ramsay; P McGlave; J H Kersey
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

6.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.

Authors:  K Pfeffer; T Matsuyama; T M Kündig; A Wakeham; K Kishihara; A Shahinian; K Wiegmann; P S Ohashi; M Krönke; T W Mak
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

7.  Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide.

Authors:  Z K Ballas
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

8.  Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha.

Authors:  M R Shalaby; B Fendly; K C Sheehan; R D Schreiber; A J Ammann
Journal:  Transplantation       Date:  1989-06       Impact factor: 4.939

9.  Interleukin 1 enhances T-dependent immune responses by amplifying the function of dendritic cells.

Authors:  S L Koide; K Inaba; R M Steinman
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

10.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  78 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.

Authors:  Bradley W Blaser; Noah R Schwind; Seth Karol; Dennis Chang; Samuel Shin; Sameek Roychowdhury; Brian Becknell; Amy K Ferketich; Donna F Kusewitt; Bruce R Blazar; Michael A Caligiuri
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

3.  Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs.

Authors:  Andreas Beilhack; Stephan Schulz; Jeanette Baker; Georg F Beilhack; Ryosei Nishimura; Enosh M Baker; Gilad Landan; Edward I Herman; Eugene C Butcher; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2007-11-07       Impact factor: 22.113

4.  Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function.

Authors:  Javaneh Abbasian; Dolores Mahmud; Nadim Mahmud; Sandeep Chunduri; Hiroto Araki; Pavan Reddy; Ronald Hoffman; Mario Arpinati; James L M Ferrara; Damiano Rondelli
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

Review 5.  Intestinal graft-versus-host disease: mechanisms and management.

Authors:  Hiroyuki Takatsuka; Tsuyoshi Iwasaki; Takahiro Okamoto; Eizo Kakishita
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice.

Authors:  Yu Yu; Dapeng Wang; Chen Liu; Kane Kaosaard; Kenrick Semple; Claudio Anasetti; Xue-Zhong Yu
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

7.  Immunomodulatory effects of vitamin D: implications for GVHD.

Authors:  J Rosenblatt; A Bissonnette; R Ahmad; Z Wu; B Vasir; K Stevenson; C Zarwan; W Keefe; B Glotzbecker; H Mills; R Joyce; J D Levine; D Tzachanis; V Boussiotis; D Kufe; D Avigan
Journal:  Bone Marrow Transplant       Date:  2010-01-18       Impact factor: 5.483

8.  Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.

Authors:  Lucie M Turcotte; Tao Wang; Michael T Hemmer; Stephen R Spellman; Mukta Arora; Ashley Yingst; Daniel Couriel; Amin Alousi; Joseph Pidala; Jennifer M Knight; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-23       Impact factor: 5.742

9.  Memory CD4+ T cells do not induce graft-versus-host disease.

Authors:  Britt E Anderson; Jennifer McNiff; Jun Yan; Hester Doyle; Mark Mamula; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

10.  Phospholipase D1 mediates TNFalpha-induced inflammation in a murine model of TNFalpha-induced peritonitis.

Authors:  Swaminathan Sethu; Peter N Pushparaj; Alirio J Melendez
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.